Newsfeeds Archive - Page 22 of 56

1 minute read

UCSF Clinical Trial Shows Promising Results For Naturally-Sourced Psilocybin And Psilocin

May 30, 8:23 PM

A Phase 1 clinical trial led by the University of California San Francisco (UCSF) assessing research partner Filament Health Corp.’s (OTCQB: FLHLF) botanical psychedelic drug candidates has shown positive interim outcomes.

FLHLF

2 minute read

Numinus’ Clinical Site Joins Compass’ Phase 3 Program On Psilocybin Therapy For TRD

By Lara Goldstein

May 30, 4:05 PM

Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for Treatment-Resistant Depression (TRD).

CMPS

2 minute read

MindMed And FCM Holdings’ Dispute Over Clinical Path Forward Deepens

By Lara Goldstein

May 30, 11:51 AM

The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis the upcoming management elections this June 15.

MNMD

2 minute read

Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session

By Lara Goldstein

May 26, 6:23 PM

Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support in cancer patients with Major Depressive Disorder (MDD) is out.

CMPS

2 minute read

Small Pharma’s IP Portfolio Grows With Numerous Approved Patent Applications Around The World

By Lara Goldstein

May 26, 11:30 AM

U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.

DMTTF

2 minute read

MindMed Calls FDA Experts To Validate LSD Drug Development Strategy

By Lara Goldstein

May 25, 2:52 PM

In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t

MNMD

2 minute read

Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes

By Lara Goldstein

May 24, 3:47 PM

Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing

CYBN

3 minute read

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK’s Parliamentary Debate And More

By Lara Goldstein

May 23, 7:56 PM

Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application covering what may be the first new salts, co-crystals and polymorphs of psilocybin in history.

ENVB

2 minute read

MEAI Compound’s First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period

By Lara Goldstein

May 22, 4:03 PM

Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of Medicine’s Psychiatry Dept. as the first U.S. site for its Phase 1/2a trial on proprietary CMND-100.

CMND